

## DAFTAR PUSTAKA

1. Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. *American Journal of Therapy*; 2000(7):115–121.
2. Loren L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. *Journal of Gastroenterology*; 2001(120):594–606.
3. IMS Health. MIDAS Quantum based on selected markets (ATC M1A oral solid forms only. US\$ Actual, growth in US\$ CER); 2008.
4. Departemen Kesehatan Republik Indonesia. Riset kesehatan dasar (RISKESDAS). Jakarta: Badan Penelitian dan Pengembangan Kesehatan, Departemen Kesehatan, Republik Indonesia; 2007.
5. Sinatra R, et al. The essence of analgesia and analgesics. Cambridge: Cambridge University Press; 2011. p. 229-230.
6. Widodo U, Bircher J, et al. Kumpulan data klinik farmakologi. Yogyakarta: Mada University Press.; 1993. p. 379.
7. Jacqueline RB, Laura DR. *Lehne's pharmacology for nursing care*. Missouri: Elsevier Saunders; 2013. p. 60-64.
8. Aronson JK. *Meyler's side effects of analgesics and anti-inflammatory drugs*. San Diego: Elsevier Science; 2010. p. 225-227.
9. Novartis. Arthrotec package insert. London: Pfizer Inc.; 2009.
10. Robert B, Andrew JF. *The Merck manual*. Jakarta: Binarupa Aksara; 1999. p. 245.
11. Satoskar RS, et al. *Pharmacology and pharmacotherapeutics*. Mumbai: Popular Prakashan; 2009. p. 159-181.
12. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. *American Journal of Epidemiology*; 2000(151):488–496.
13. Atta MG, Whelton A. Acute renal papillary necrosis induced by ibuprofen.


- American Journal of Therapeutics; 1997(4):55–60.
14. Sandhu GK, Heyneman CA. Nephrotoxic potential of selective cyclooxygenase-2 inhibitors. *Annals of Pharmacotherapy*; 2004(38):700–704.
  15. Harris RC. COX-2 and the kidney. *Journals of Cardiovascular Pharmacology*; 2006(47): 537–542.
  16. Yasmeen T, et al. Adverse effects of diclofenac sodium on renal parenchyma of adult albino rats. *Jinnah Postgraduate Medical Journal*; 2007:57(7):349-351.
  17. Taib N JB. Histochemical alterations in the spleen of rabbits induced by diclofenac sodium (Voltaren). *J. King Saud Univ., Vol. 19, Science(1)*. 2006;: p. 21-29.
  18. Aprioku JS, et al. Renal effects of non-steroidal anti-inflammatory drugs in albino rats. *British Journal of Pharmaceutical Research*. 2013; 3(3): 314-325.
  19. Jacobson RH, et al. *The principles and practice of nephrology*. Philadelphia: B.C. Decker Inc.; 1991. p.338-339.
  20. Merskey NB. *Classification of chronic pain*. Seattle: IASP Press; 1994. p.28.
  21. Soenarjo D. *Anestesiologi*. Semarang: Perhimpunan Dokter Spesialis Anestesi dan Terapi Intensif Cabang Jawa Tengah; 2013. p.309-310.
  22. Latief SA, et al. *Petunjuk praktis anestesiologi*. Jakarta: Bagian Anestesiologi dan Terapi Intensif Fakultas Kedokteran Universitas Indonesia; 2007. p.74.
  23. McQuay HJ, Moore RA. *An evidence-based resource for pain relief*. Oxford: Oxford University Press, 2000. p. 202.
  24. Sudoyo AW, et al. *Buku ajar ilmu penyakit dalam*. Jakarta: InternaPublishing; 2009. p.2042.
  25. Laurence LB, et al. *Goodman & Gilman's the pharmacological basis of therapeutics*. California: McGraw-Hill Companies, Inc.; 2006. p. 653-671.
  26. Ajjan RA, et al. *Autoimmune reactions*. New York: Humana Press Inc.; 1999. p.6-7.

27. Craig CR, et al. Modern pharmacology with clinical application. Philadelphia: Lippincott Williams & Wilkins; 2004. p.423-427.
28. Katzung B, et al. Basic & clinical pharmacology. San Francisco: The McGraw-Hill Companies, Inc; 2012. p.636-641.
29. Syarif A, et al. Farmakologi dan terapi. Jakarta: Gaya Baru; 2007. p.230-232.
30. Marjoribanks J, Proctor ML, Farquhar C. Non-steroidal anti inflammatory drugs for primary dysmenorrhoea. Cochrane Database Syst. Rev; 2003.
31. Richard D, Wayne JK, Adam WM. Gray's anatomy for students. Philadelphia: Elsevier; 2010. p.323.
32. Underwood JC. Patologi umum dan sistemik. Jakarta: EGC; 1999. p.665-668.
33. Guyton AC, et al. Textbook of medical physiology. Pennsylvania: Elsevier; 2006. p. 323-325.
34. Tortora GJ, Derrickson B. Principles of anatomy and physiology. New Jersey: John Wiley & Sons; 2011. p.1074-1077.
35. Talwar GP, Srivastava LM. Textbook of biochemistry and human biology. New Delhi: Prentice Hall of India Private; 2006. p.406-407.
36. Murray RK, et al. Harper's illustrated biochemistry. San Francisco: The McGraw-Hill Companies, Inc.; 2006. p.147-152.
37. Ramakrishnan S, Prasannan KG, Rajan R. Textbook of medical biochemistry. New Delhi: Orient Langman Private Limited; 2004. p.294.
38. Roger T, Baron KW. Physiology. New York: Springer-Verlag. New York, Inc.; 1995. p.154-156.
39. Ying-Chun M, et al. Different plasma creatinine assays and impact on glomerular filtration rate. American Journal of Kidney Diseases. 2007;45:463-472.
40. William JM, Stephen KB. Clinical biochemistry: metabolic and clinical aspects. Philadelphia: Elsevier; 2008.
41. Gibson RS. Principles of nutritional assessment. New York: Oxford

- University Press Inc.; 2005. p.407-408.
42. Schrier RW. Manual of nephrology. Philadelphia: Lippincott Williams & Wilkins; 2009. p.214-215.
  43. Fischbach FT, Dunning MB. A manual of laboratory and diagnostic tests. Philadelphia: Lippincott Williams & Wilkins; 2009. p.274.
  44. Matthew RW, et al. Renal effects of nonselective NSAIDs and coxibs. Cleveland Clinic Journal of Medicine. 2010;69(1):423-431.
  45. Whelton A. Renal and related cardiovascular effects of conventional and COX-2- specific NSAIDs and non-NSAID analgesics. American Journal of Theurapeutic. 2000; 7: p. 63-74.
  46. Hörl WH. Nonsteroidal anti-inflammatory drugs and the kidney. Pharmaceutical Journal. 2010; 3(7): p. 2291-2321.
  47. Kumar V, Cotran RS, Robbins Sl. Buku Ajar Patologi. EGC: Jakarta; 2008. p. 8-9.
  48. Claudio RM. Critical care nephrology. Canada: Elsevier; 2009. p.317-324.
  49. U.S. National Library of Medicine [Internet]. Maryland: U.S. National Library of Medicine; c1993 [updated 2015 June 19; cited 2015 June 29]. Available from: <http://www.nlm.nih.gov>.
  50. Brenner BM. Brenner & Rector's the kidney. Philadelphia: Saunders Elsevier; 2008. p. 783-786.

## LAMPIRAN

### Lampiran 1. Ethical Clearance

	<p><b>KOMISI ETIK PENELITIAN KESEHATAN (KEPK) FAKULTAS KEDOKTERAN UNIVERSITAS DIPONEGORO DAN RSUP dr KARIADI SEMARANG</b> Sekretariat : Kantor Dekanat FK Undip Lt.3 Jl. Dr. Soetomo 18. Semarang Telp/Fax. 024-8318350</p>	
<b>ETHICAL CLEARANCE</b> <b>No.172/EC/FK-RSDK/2015</b>		
Komisi Etik Penelitian Kesehatan Fakultas Kedokteran Universitas Diponegoro- RSUP. Dr. Kariadi Semarang, setelah membaca dan menelaah Usulan Penelitian :		
<b>Judul</b>	: Pengaruh pemberian Natrium Diklofenak dosis 1,4 MG/KgBB dan 2,8 MG/KgBB terhadap Kadar Ureum tikus wistar	
<b>Peneliti</b>	: <b>Lailitifa Windy Subekti</b>	
<b>Judul</b>	: Pengaruh pemberian Natrium Diklofenak dosis 1,4 MG/KgBB dan 2,8 MG/KgBB terhadap Kadar Serum Kreatinin tikus wistar	
<b>Peneliti</b>	: <b>Indriyani Mangampa</b>	
<b>Pembimbing</b>	: dr. Taufik Eko N., M.Si.Med, Sp. An	
<b>Penelitian</b>	: Dilaksanakan di :	
	1. Laboratorium Fisiowahan Fakultas Matematika dan Ilmu Pengetahuan Alam (MIPA) Biologi Universitas Negeri Semarang (UNNES)	
	2. Bagian Patologi Klinik RSUP Dr. Kariadi Semarang	
Setuju untuk dilaksanakan, dengan memperhatikan prinsip-prinsip yang dinyatakan dalam Deklarasi Helsinki 1975, yang diamended di Seoul 2008 dan Pedoman Nasional Etik Penelitian Kesehatan (PNEPK) Departemen Kesehatan RI 2011		
Pada laporan akhir peneliti harus melampirkan cara pemeliharaan & dekapitasi hewan coba dan melaporkan ke KEPK bahwa penelitian sudah selesai dilampiri Abstrak Penelitian.		
Semarang, <b>07 APR 2015</b>		
Komisi Etik Penelitian Kesehatan Fakultas Kedokteran Undip-RS. Dr. Kariadi Sekretaris		
		
<b>Dr. dr. Selamat Budijitno, M.Si.Med, Sp.B, Sp.B(K), Onk, FICS</b> NIP. 19710807 200812 1 001		

**Lampiran 2.** Surat ijin melakukan penelitian di Laboratorium Jurusan Biologi  
FMIPA Universitas Negeri Semarang



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN  
UNIVERSITAS NEGERI SEMARANG  
FAKULTAS MATEMATIKA DAN ILMU PENGETAHUAN ALAM  
LABORATORIUM JURUSAN BIOLOGI

Alamat : Gedung D11 FMIPA UNNES Kampus Sekaran Gunungpati Semarang 50229

**SURAT KETERANGAN**

No. 498 /UN. 37.1.4.5/PP/2015

Yang bertanda tangan di bawah ini, Ketua Jurusan Biologi FMIPA Universitas Negeri Semarang menerangkan bahwa mahasiswa berikut :

Nama : Indriyani Mangampa  
NIM : 22010111130119  
Fakultas/ Universitas : Kedokteran/ UNDIP Semarang  
Judul : Pengaruh Pemberian Natrium Diklofenak dosis 1,4 mg/kgbb dan 2,8 mg/kgbb terhadap Kreatinin Tikus Wistar

telah melakukan penelitian di Laboratorium Jurusan Biologi FMIPA Universitas Negeri Semarang pada bulan Mei 2015

Demikian Surat Keterangan ini kami buat untuk dapat digunakan sebagaimana perlunya.

Semarang, 20 Mei 2015

Mengetahui  
Ketua Jurusan Biologi FMIPA UNNES



Andri Irsadi, S.Pd, M.Si  
NIP. 1974.03.1020.0003.1001

Kepala Laboratorium

*Lina Herlina*  
Dra. Lina Herlina, M.Si  
NIP. 19670207.199203.2001

**Lampiran 3 . Data SPSS**

Kelompok	Tikus Ke-	Kadar Serum Kreatinin (mg/dl)
Kontrol	1	0,88
	2	0,82
	3	1,01
	4	1,35
	5	1,36
Perlakuan 1	1	0,74
	2	0,94
	3	0,79
	4	0,79
	5	0,71
Perlakuan 2	1	0,73
	2	0,86
	3	1,04
	4	0,81
	5	0,70

**Case Processing Summary**

DOSIS NATRIUM DIKLOFENAK	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
KADAR .00	5	100.0%	0	0.0%	5	100.0%
SERUM 1.40	5	100.0%	0	0.0%	5	100.0%
KREATINI 2.80	5	100.0%	0	0.0%	5	100.0%
N						

**Descriptives**

DOSIS NATRIUM DIKLOFENAK		Statistic	Std. Error	
KADAR SERUM KREATININ	Mean	1.0840	.11483	
	95% Confidence Interval for Mean	Lower Bound	.7652	
		Upper Bound	1.4028	
	5% Trimmed Mean	1.0833		
	Median	1.0100		
	Variance	.066		
	.00 Std. Deviation	.25677		
	Minimum	.82		
	Maximum	1.36		
	Range	.54		
	Interquartile Range	.51		
	Skewness	.309	.913	
	Kurtosis	-2.988	2.000	
	1.40	Mean	.9760	.16446
95% Confidence Interval for Mean		Lower Bound	.5194	
		Upper Bound	1.4326	
5% Trimmed Mean		.9533		
Median		.7900		
Variance		.135		
Std. Deviation	.36774			



	Minimum		.74	
	Maximum		1.62	
	Range		.88	
	Interquartile Range		.52	
	Skewness		2.020	.913
	Kurtosis		4.133	2.000
	Mean		.8280	.06012
	95% Confidence Interval for Mean	Lower Bound	.6611	
		Upper Bound	.9949	
	5% Trimmed Mean		.8233	
	Median		.8100	
	Variance		.018	
2.80	Std. Deviation		.13442	
	Minimum		.70	
	Maximum		1.04	
	Range		.34	
	Interquartile Range		.24	
	Skewness		1.118	.913
	Kurtosis		1.118	2.000

#### Tests of Normality


DOSIS NATRIUM DIKLOFENAK		Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
KADAR	.00	.250	5	.200*	.846	5	.182
SERUM	1.40	.339	5	.062	.713	5	.013
KREATININ	2.80	.206	5	.200*	.916	5	.506

\*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

**Test of Homogeneity of Variance**

		Levene Statistic	df1	df2	Sig.
KADAR SERUM KREATININ	Based on Mean	1.580	2	12	.246
	Based on Median	.392	2	12	.684
	Based on Median and with adjusted df	.392	2	5.881	.692
	Based on trimmed mean	1.227	2	12	.328



**Data Transformasi**

**Case Processing Summary**

DOSIS NATRIUM DIKLOFENAK		Cases					
		Valid		Missing		Total	
		N	Percent	N	Percent	N	Percent
Kadar	.00	5	100.0%	0	0.0%	5	100.0%
Serum	1.40	5	100.0%	0	0.0%	5	100.0%

Kreatin in (transfo rmed)	2.80	5	100.0%	0	0.0%	5	100.0%
------------------------------------	------	---	--------	---	------	---	--------

**Descriptives**

DOSIS NATRIUM DIKLOFENAK		Statistic	Std. Error
	Mean	.9644	.09946
	95% Confidence Interval for Mean	Lower Bound Upper Bound	.6883 1.2405
	5% Trimmed Mean	.9630	
	Median	.9901	
	Variance	.049	
	.00 Std. Deviation	.22239	
	Minimum	.74	
	Maximum	1.22	
	Range	.48	
	Interquartile Range	.44	
	Skewness	-.057	.913
Kadar Serum Kreatin in (transfo rmed)	Kurtosis	-2.701	2.000
	Mean	1.1128	.13260
	95% Confidence Interval for Mean	Lower Bound Upper Bound	.7447 1.4810
	5% Trimmed Mean	1.1271	
	Median	1.2658	
	Variance	.088	
	1.40 Std. Deviation	.29651	
	Minimum	.62	
	Maximum	1.35	
	Range	.73	
	Interquartile Range	.47	
	Skewness	-1.615	.913
	Kurtosis	2.453	2.000
	Mean	1.2315	.08234
	2.80 95% Confidence Interval for	Lower Bound	1.0029

Mean	Upper Bound	1.4601	
5% Trimmed Mean		1.2355	
Median		1.2346	
Variance		.034	
Std. Deviation		.18411	
Minimum		.96	
Maximum		1.43	
Range		.47	
Interquartile Range		.34	
Skewness		-.646	.913
Kurtosis		-.160	2.000

#### Tests of Normality


DOSIS NATRIUM DIKLOFENAK	Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Kadar .00	.243	5	.200*	.880	5	.311
Serum 1.40	.297	5	.171	.819	5	.115
Kreatin in (transfo rmed) 2.80	.174	5	.200*	.958	5	.793

\*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

#### Test of Homogeneity of Variance

	Levene Statistic	df1	df2	Sig.
Kadar Based on Mean	.532	2	12	.601
Serum Based on Median	.119	2	12	.889
Kreatin Based on Median and with in adjusted df	.119	2	6.552	.890
(transfo rmed) Based on trimmed mean	.485	2	12	.627



### Descriptives

Kadar Serum Kreatinin (transformed)

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Minimum	Maximum	Between-Component Variance
					Lower Bound	Upper Bound			
.00	5	.9644	.22239	.09946	.6883	1.2405	.74	1.22	
1.40	5	1.1128	.29651	.13260	.7447	1.4810	.62	1.35	
2.80	5	1.2315	.18411	.08234	1.0029	1.4601	.96	1.43	
Total	15	1.1029	.24844	.06415	.9653	1.2405	.62	1.43	
Model			.23894	.06169	.9685	1.2373			
Fixed Effects									
Random Effects				.07725	.7705	1.4353			.00649

## One Way ANOVA

### ANOVA

Kadar serum kreatinin (transformed)

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	.179	2	.090	1.568	.248
Within Groups	.685	12	.057		
Total	.864	14			

## Post Hock Tests

### Multiple Comparisons

Dependent Variable: kadar serum kreatinin (transformed)

LSD

(I) DOSIS NATRIUM DIKLOFENA K	(J) DOSIS NATRIUM DIKLOFENA K	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
.00	1.40	-.14842	.15112	.345	-.4777	.1808
	2.80	-.26706	.15112	.103	-.5963	.0622
1.40	.00	.14842	.15112	.345	-.1808	.4777
	2.80	-.11864	.15112	.448	-.4479	.2106
2.80	.00	.26706	.15112	.103	-.0622	.5963
	1.40	.11864	.15112	.448	-.2106	.4479

## **Lampiran 4. Biodata Mahasiswa**

### **BIODATA MAHASISWA**

Nama : Indriyani Mangampa  
NIM : 22010111130119  
Tempat/tanggal lahir : Jakarta 13 Juli 1991  
Jenis Kelamin : Perempuan  
Alamat : Perumahan Sukamaju Permai Blok T. No 8, Depok  
Nomor Telepon : 081299419067  
e-mail : [indrimangampa@gmail.com](mailto:indrimangampa@gmail.com)

### **Riwayat Pendidikan Formal**

1. SD : SD Mardi Yuana Lulus tahun: 2003
2. SMP : SMP Mardi Yuana Lulus tahun: 2006
3. SMA : SMA N 26 Jakarta Lulus tahun: 2009
4. FK UNDIP : Masuk tahun: 2011

**Lampiran 5. Dokumentasi Penelitian**





